Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Summary

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to adults with extensive-stage small cell lung cancer (ES-SCLC), a fast-growing type of lung cancer that has spread widely in the body. To join the study, participants must meet the following conditions: Be 18 years or older. Have extensive-stage small cell lung cancer confirmed by lab tests. Have not received chemotherapy or radiation for this type of lung cancer. Be in good physical condition and have healthy organs based on medical tests.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Small Cell Lung Cancer (SCLC)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2/3

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites